Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?

about

Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries

P2860

Q30245434-CBF12CC4-0910-4C21-8420-D1E6A8CE4677 Q36989863-348B5F41-943D-449B-9BD9-1CDC4CCAA758

P2860

Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?

Item

http://www.wikidata.org/entity/Q38057771

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Does prophylaxis with palivizu ...... dren less than 2 years of age?

@en

type

Item

label

Does prophylaxis with palivizu ...... dren less than 2 years of age?

@en

prefLabel

Does prophylaxis with palivizu ...... dren less than 2 years of age?

@en

P1476

Does prophylaxis with palivizu ...... dren less than 2 years of age?

@en

P2093

Bosco Paes

http://www.w3.org/2001/XMLSchema#string

Oluwole Oni

http://www.w3.org/2001/XMLSchema#string

Peter Greally

http://www.w3.org/2001/XMLSchema#string

Taha Hassan

http://www.w3.org/2001/XMLSchema#string

P2860

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis

Management of infants with cystic fibrosis: a summary of the evidence for the cystic fibrosis foundation working group on care of infants with cystic fibrosis.

Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group.

Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group.

Preventing respiratory syncytial virus infections.

The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.

Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children.

Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa.

RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells.

P304

1033-1038

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1440-1754.2012.02593.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Basil Elnazir

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23126393

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

hospitalization

Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?

about

P2860

P2860

Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921